GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
W

Wuhan Keqian Biology Co 688526.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

11.56

-0.69%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Wuhan Keqian Biology Co

Its shares trade on Shanghai under the ticker 688526.SS. It has been listed since 22 September 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥950.3m and net income of CN¥415.6m. At that date it held total assets of CN¥4.79bn and shareholders' equity of CN¥4.17bn.

Wuhan Keqian Biology Co., Ltd. engages in the research, development, production, and sale of veterinary biological products. The company is headquartered in Wuhan, Hubei. The company went IPO on 2020-09-22. The firm's main products are vaccines for swine and poultry. The firm mainly conducts its businesses within the China market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
22 Sept 2020
Employees
860
Website
kqbio.com ↗

Leadership

Pay as last reported

  • Ms. Mulin ChenChairman of the Board, General ManagerCN¥1.6m
  • Mr. Ming ZhongVice Chairman of the Board, Chief Financial Officer, Deputy General Manager, since 2020CN¥1.6m
  • Mr. Huanchun ChenChief Scientific Officer, since 2000
  • Mr. Guanping ChenDeputy General ManagerCN¥1.6m
  • Mr. Deng HongDeputy General Manager
  • Mr. Xibiao TangDeputy General ManagerCN¥4.0m
  • Mr. Gaoyuan XuExecutive Deputy General Manager,Research and Development DirectorCN¥1.8m
  • Mr. Mingguang ZhouDeputy Chief EngineerCN¥636,500
  • Ms. Tiantian ZouSecretary of the Board
  • Ms. Liurong FangDirector
  • Mr. Qigai HeDirector
  • Mr. Chunquan LiuDirector

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Wuhan Keqian Biology Co Ltd employs 860 full-time employees in the Health Care sector.
  • The company focuses on veterinary biological products including swine and poultry vaccines.
  • Wuhan Keqian operates primarily within the China market for its veterinary products.

Weaknesses

  • The company's business is limited to the China market without international expansion.
  • Wuhan Keqian relies solely on veterinary biological products without diversification.
  • The firm has no mention of international markets or global partnerships in its operations.

Opportunities

  • The growing demand for veterinary vaccines in China presents significant market opportunities.
  • Expanding into international markets could leverage Wuhan Keqian's expertise in veterinary products.
  • Increasing focus on animal health in China may drive further product development.

Threats

  • Dependence on the China market exposes Wuhan Keqian to domestic economic fluctuations.
  • Lack of product diversification makes the company vulnerable to market changes.
  • No international presence could limit growth potential in global veterinary markets.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.